Table 5.
Characteristics | All (n = 344) | T6SS‐positive (n = 69) | T6SS‐negative (n = 275) | P value |
---|---|---|---|---|
Age | 42.69 ± 25.83 | 41.96 ± 24.76 | 42.86 ± 26.13 | .684 |
Gender | ||||
Male | 210(61.0%) | 45(65.2%) | 165(60.0%) | .427 |
Female | 134(39.0%) | 24(34.8%) | 110(40.0%) | |
Acquisition | ||||
Community‐acquired | 192(55.8%) | 46(66.7%) | 146(53.1%) | .042* |
Hospital‐acquired | 152(44.2%) | 23(33.3%) | 129(46.9%) | |
Primary site | ||||
Respiratory tract | 212(61.6%) | 42(60.9%) | 170(61.8%) | .885 |
Biliary tract | 15(4.4%) | 1(1.4%) | 14(5.1%) | .321 |
Intra‐abdomen | 38(11.0%) | 5(7.2%) | 33(12.0%) | .260 |
Liver abscess | 10(2.9%) | 5(7.2%) | 5(1.8%) | .016* |
Brain | 13(3.8%) | 4(5.8%) | 9(3.3%) | .326 |
Urinary tract | 12(3.5%) | 3(4.3%) | 9(3.3%) | .663 |
Others | 44(12.8%) | 9(13.0%) | 35(12.7%) | .944 |
Personal history | ||||
Smoking history | 69(20.1%) | 12(17.4%) | 57(20.7%) | .536 |
Drinking history | 63(18.3%) | 10(14.5%) | 53(19.3%) | .359 |
Chemotherapy history | 58(16.9%) | 12(17.4%) | 46(16.7%) | .895 |
Blood transfusion history | 26(7.6%) | 3(4.3%) | 23(8.4%) | .318 |
Underlying condition | ||||
Hypertension | 83(24.1%) | 17(24.6%) | 66(24.0%) | .912 |
Cancer | 59(17.2%) | 12(17.4%) | 47(17.1%) | .953 |
Diabetes mellitus | 55(16.0%) | 14(20.3%) | 41(14.9%) | .276 |
Premature baby | 44(12.8%) | 12(17.4%) | 32(11.6%) | .201 |
Hematological diseases | 41(11.9%) | 7(10.1%) | 34(12.4%) | .611 |
Biliary tract disease | 36(10.5%) | 11(15.9%) | 25(9.1%) | .096 |
Pulmonary infection | 33(9.6%) | 6(8.7%) | 27(9.8%) | .777 |
Acute severe pancreatitis | 28(8.1%) | 6(8.7%) | 22(8.0%) | .850 |
Liver cirrhosis | 13(3.8%) | 3(4.3%) | 10(3.6%) | .729 |
Multiple bacterial infections | 66(19.2%) | 11(15.9%) | 55(20.0%) | .444 |
Septic shock | 85(24.7%) | 13(18.8%) | 72(26.2%) | .206 |
Death in hospital | 19(5.5%) | 6(8.7%) | 13(4.7%) | .197 |
A P value < .05 was considered to be statistically significant.